AETERNA ZENTARIS INC (AEZS)
CA0079755017 - Common Stock
Aeterna Zentaris Announces Effective Date of Share Consolidation
TORONTO, ON, May 01, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) announces that it has filed...
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
AEZS Stock Earnings: AEterna Zentaris Misses EPS for Q4 2023
AEZS stock results show that AEterna Zentaris missed analyst estimates for earnings per share the fourth quarter of 2023.
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected...
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
Aeterna Zentaris Board recommends shareholders vote FOR all resolutions, to create a diversified biopharmaceutical company with a compelling value...
Aeterna Zentaris files to sell 2.53M warrants (NASDAQ:AEZS)
Aeterna Zentaris (NASDAQ:AEZS) disclosed in an SEC filing on Thursday a prospectus to offer and sell 2.53 million warrants.SEC filing.More on Aeterna...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, EVFM, AEZS, HOLI
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
AEZS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aeterna Zentaris Inc. Is Fair to Shareholders
Aeterna Zentaris and Ceapro to merge in all-stock deal
Aeterna Zentaris (AEZS) and Ceapro (CRPOF) announce an all-stock merger to create a single biopharmaceutical company traded on Nasdaq and TSX. Read more here.
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company
TORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSXV: CZO) (OTCQX:...
Aeterna Zentaris Reports Second Quarter 2023 Financial Results
Ended the quarter with $42.2 million in cash, expected to fund operations into 2025Driving patient recruitment for Phase 3 DETECT trial for the diagnosis...
Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update
Highlights progress, recent developments and upcoming key milestonesCompany continues to build growing body of data across pipeline, advancing towards...
Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series
Live moderated video webcast on Thursday, July 13th at 10:00 AM ET TORONTO, ONTARIO, July 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:...
Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders
TORONTO, ONTARIO, June 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty...
Aeterna Zentaris Reports First Quarter 2023 Financial Results
– Ended the quarter with $46.6 million in cash, expected to fund operations into 2025 – Continued efforts to accelerate recruitment for DETECT trial ...
Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial
U.S. sales of Macrilen® for adult use to be temporarily discontinued as of May 23, 2023, while DETECT trial continues in order to expand the opportunity...
Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results
– Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025– Executing strategy to streamline advancement...
Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)
Pharmanovia to acquire license to GHRYVELIN™ from Aeterna Zentaris’ existing licensee, Consilient Health, effective immediately TORONTO, ONTARIO, March ...
Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones
Aeterna Zentaris focused on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen™ in the U.S. and CanadaCompany...
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS)...
Aeterna Zentaris Reports Third Quarter 2022 Financial Results
– Company ended the quarter with $53.8 million in cash – Driving continued progress across diversified pre-clinical and clinical development...
Aeterna Zentaris Reports Third Quarter 2022 Financial Results
Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk
– Company plans to prioritize efforts to identify new strategic development and commercialization partner – Company is in a strong position that...
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights
– Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline ...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with a breakdown of the biggest pre-market stock movers investors will want to watch on Tuesday!
Aeterna Zentaris Announces Effective Date of Share Consolidation
TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty...
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty...